Literature DB >> 22079770

Effects of MDMA and related analogs on plasma 5-HT: relevance to 5-HT transporters in blood and brain.

Samanta Yubero-Lahoz1, Mario A Ayestas, Bruce E Blough, John S Partilla, Richard B Rothman, Rafael de la Torre, Michael H Baumann.   

Abstract

(±)-3,4-Methylenedioxymethamphetamine (MDMA) is an illicit drug that evokes transporter-mediated release of serotonin (5-HT) in the brain. 5-HT transporter (SERT) proteins are also expressed in non-neural tissues (e.g., blood), and evidence suggests that MDMA targets platelet SERT to increase plasma 5-HT. Here we tested two hypotheses related to the effects of MDMA on circulating 5-HT. First, to determine if MDMA metabolites might contribute to actions of the drug in vivo, we used in vitro microdialysis in rat blood specimens to examine the effects of MDMA and its metabolites on plasma 5-HT. Second, to determine whether effects of MDMA on plasma 5-HT might be used as an index of central SERT activity, we carried out in vivo microdialysis in blood and brain after intravenous MDMA administration. The in vitro results show that test drugs evoke dose-related increases in plasma 5-HT ranging from two- to sevenfold above baseline, with MDMA and its metabolite, (±)-3,4-methylenedioxyamphetamine (MDA), producing the largest effects. The ability of MDMA and related analogs to elevate plasma 5-HT is correlated with their potency as SERT substrates in rat brain synaptosomes. The in vivo results reveal that MDMA causes concurrent increases in extracellular 5-HT in blood and brain, but there are substantial individual differences in responsiveness to the drug. Collectively, our findings indicate that MDMA and its metabolites increase plasma 5-HT by a SERT-dependent mechanism, and suggest the possibility that measures of evoked 5-HT release in blood may reflect central SERT activity. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22079770      PMCID: PMC3253888          DOI: 10.1016/j.ejphar.2011.10.033

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  37 in total

Review 1.  Development of effective PET and SPECT imaging agents for the serotonin transporter: has a twenty-year journey reached its destination?

Authors:  Yiyun Huang; Ming-Qiang Zheng; John M Gerdes
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

2.  A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity.

Authors:  A Heinz; D W Jones; C Mazzanti; D Goldman; P Ragan; D Hommer; M Linnoila; D R Weinberger
Journal:  Biol Psychiatry       Date:  2000-04-01       Impact factor: 13.382

3.  Effect of physiologic shear stresses and calcium on agonist-induced platelet aggregation, secretion, and thromboxane A2 formation.

Authors:  Delia Viisoreanu; Adrian Gear
Journal:  Thromb Res       Date:  2007-02-15       Impact factor: 3.944

4.  The effect of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus.

Authors:  Mary L Forsling; John K Fallon; Darshna Shah; Gary S Tilbrook; David A Cowan; Andrew T Kicman; Andrew J Hutt
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

5.  Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?

Authors:  Kelly M Chin; Richard N Channick; Lewis J Rubin
Journal:  Chest       Date:  2006-12       Impact factor: 9.410

6.  Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization.

Authors:  S Ramamoorthy; A L Bauman; K R Moore; H Han; T Yang-Feng; A S Chang; V Ganapathy; R D Blakely
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

7.  Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults.

Authors:  Erin A Kolbrich; Robert S Goodwin; David A Gorelick; Robert J Hayes; Elliot A Stein; Marilyn A Huestis
Journal:  Ther Drug Monit       Date:  2008-06       Impact factor: 3.681

8.  The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release.

Authors:  G Rudnick; S C Wall
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

9.  Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters.

Authors:  S Schuldiner; S Steiner-Mordoch; R Yelin; S C Wall; G Rudnick
Journal:  Mol Pharmacol       Date:  1993-12       Impact factor: 4.436

Review 10.  A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters.

Authors:  S D Robertson; H J G Matthies; A Galli
Journal:  Mol Neurobiol       Date:  2009-02-06       Impact factor: 5.590

View more
  8 in total

1.  Substituted methcathinones differ in transporter and receptor interactions.

Authors:  Amy J Eshleman; Katherine M Wolfrum; Meagan G Hatfield; Robert A Johnson; Kevin V Murphy; Aaron Janowsky
Journal:  Biochem Pharmacol       Date:  2013-04-10       Impact factor: 5.858

2.  Stimulants and Pulmonary Arterial Hypertension: An Update.

Authors:  Ramon L Ramirez; Vinicio De Jesus Perez; Roham T Zamanian
Journal:  Adv Pulm Hypertens       Date:  2018

3.  Psychosis from a bath salt product containing flephedrone and MDPV with serum, urine, and product quantification.

Authors:  Stephen L Thornton; Roy R Gerona; Christian A Tomaszewski
Journal:  J Med Toxicol       Date:  2012-09

4.  Characterization of electroencephalographic and biochemical responses at 5-HT promoting drug-induced onset of serotonin syndrome in rats.

Authors:  Zhiyuan Ma; Mary Rudacille; Howard M Prentice; Rui Tao
Journal:  J Neurochem       Date:  2013-01-28       Impact factor: 5.372

Review 5.  Methamphetamine-induced toxicity: an updated review on issues related to hyperthermia.

Authors:  Rae R Matsumoto; Michael J Seminerio; Ryan C Turner; Matthew J Robson; Linda Nguyen; Diane B Miller; James P O'Callaghan
Journal:  Pharmacol Ther       Date:  2014-05-14       Impact factor: 12.310

6.  5-HTTLPR Genotype Moderates the Effects of Past Ecstasy Use on Verbal Memory Performance in Adolescent and Emerging Adults: A Pilot Study.

Authors:  Natasha E Wright; Judith A Strong; Erika R Gilbart; Skyler G Shollenbarger; Krista M Lisdahl
Journal:  PLoS One       Date:  2015-07-31       Impact factor: 3.240

7.  A neuroendocrine mechanism of co-morbidity of depression-like behavior and myocardial injury in rats.

Authors:  Wang Xinxing; Liu Wei; Wu Lei; Zhan Rui; Jin Baoying; Qian Lingjia
Journal:  PLoS One       Date:  2014-02-13       Impact factor: 3.240

8.  Platelet serotonin transporter function predicts default-mode network activity.

Authors:  Christian Scharinger; Ulrich Rabl; Christian H Kasess; Bernhard M Meyer; Tina Hofmaier; Kersten Diers; Lucie Bartova; Gerald Pail; Wolfgang Huf; Zeljko Uzelac; Beate Hartinger; Klaudius Kalcher; Thomas Perkmann; Helmuth Haslacher; Andreas Meyer-Lindenberg; Siegfried Kasper; Michael Freissmuth; Christian Windischberger; Matthäus Willeit; Rupert Lanzenberger; Harald Esterbauer; Burkhard Brocke; Ewald Moser; Harald H Sitte; Lukas Pezawas
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.